Other substances

Tafenoquine

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Tafenoquine inhibits replication of SARS-Cov-2 at pharmacologically relevant concentrations in vitro Preprint	VERO E6 cell cultures		4-times more potent than hydroxychloroquine	Jul/12/2020

AI-suggested references

Link	Publication date
Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.	Jul/01/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04533347	Tafenoquine in Patients With Mild to Moderate COVID-19	Active, not recruiting	Phase 2	Feb/19/2021	Feb/28/2022
Alternative id - TQ 2020_06 Interventions - Drug: Tafenoquine Oral Tablet\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Deluxe Health Center LLC, Miami, Florida, United States\|Hope Clinical Trials, Miami, Florida, United States\|F&T Medical Research, Inc., Miami, Florida, United States\|Kendall South Medical Center, Inc., Miami, Florida, United States\|Skyline Medical Center, Elkhorn, Nebraska, United States\|Burke Primary Care, Morgantown, North Carolina, United States\|AFC Urgent Care, Easley, South Carolina, United States\|Centex Studies, Brownsville, Texas, United States\|Care United, Forney, Texas, United States\|Clinical Trial Network, Houston, Texas, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 275 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Proportion of patients with clinical recovery of COVID-19 symptoms on Day 14\|Increases the proportion of patients with absence of clinical symptoms by individual symptom at Day 14\|Decreases the hospitalization rate due to COVID-19 by Day 14\|Decreases the number of medical follow-up visits by Day 14.